These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35875967)

  • 21. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring Spatial-Temporal Changes in
    Kyriakopoulos CE; Heath EI; Ferrari A; Sperger JM; Singh A; Perlman SB; Roth AR; Perk TG; Modelska K; Porcari A; Duggan W; Lang JM; Jeraj R; Liu G
    J Clin Oncol; 2020 Nov; 38(31):3662-3671. PubMed ID: 32897830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response assessment using [
    Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
    Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Role of
    Lunger L; Chantadisai M; Karimzadeh A; Rauscher I; D'Alessandria C; Feuerecker B; Langbein T; Tauber R; Schiele S; Weber W; Eiber M
    J Nucl Med; 2023 Jun; 64(6):896-901. PubMed ID: 36581373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
    Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Garg I; Nathan MA; Packard AT; Kwon ED; Larson NB; Lowe V; Davis BJ; Haloi R; Mahon ML; Goenka AH
    J Cancer Res Ther; 2021; 17(2):358-365. PubMed ID: 33063697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients.
    Caffo O; Maines F; Donner D; Veccia A; Chierichetti F; Galligioni E
    Clin Genitourin Cancer; 2014 Oct; 12(5):312-6. PubMed ID: 24806400
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging of Prostate Cancer Using
    Castellucci P; Ceci F; Fanti S
    PET Clin; 2017 Apr; 12(2):137-143. PubMed ID: 28267448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Algorithm Guided by Sequential 11C-Choline PET/CT in a Patient With Metastatic Castration-Resistant Prostate Cancer.
    Garcia Garzon JR; Bassa P; Soler M; Moragas M; Llinares E; Riera E
    Clin Nucl Med; 2015 Jul; 40(7):600-1. PubMed ID: 25742237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of
    Fossati N; Scarcella S; Gandaglia G; Suardi N; Robesti D; Boeri L; Karnes RJ; Heidenreich A; Pfister D; Kretschmer A; Buchner A; Stief C; Battaglia A; Joniau S; Van Poppel H; Osmonov D; Juenemann KP; Shariat S; Hiester A; Nini A; Albers P; Tilki D; Graefen M; Gill IS; Mottrie A; Galosi AB; Montorsi F; Briganti A
    J Urol; 2020 Aug; 204(2):296-302. PubMed ID: 32068488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between local recurrences and distant metastases in prostate cancer: can
    Giovacchini G; Ciarmiello A; Giovannini E; Fodor A; Cozzarini C; Mapelli P; Incerti E; Di Muzio N; Gianolli L; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):962-969. PubMed ID: 29453702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT.
    Kitajima K; Yamamoto S; Kawanaka Y; Komoto H; Shimatani K; Hanasaki T; Taguchi M; Nagasawa S; Yamada Y; Kanematsu A; Yamakado K
    Medicine (Baltimore); 2021 Jun; 100(23):e26206. PubMed ID: 34115004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
    Filippi L; Frantellizzi V; Chiaravalloti A; Pontico M; De Feo MS; Corica F; Montebello M; Schillaci O; De Vincentis G; Bagni O
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of [
    Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
    PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.